Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents surrounding Alexion’s rare diseases blockbuster, Soliris.
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatme
Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA.